A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404Oral Liquid Combined With Pemetrexed + Cisplatin Therapy in Patients With Advanced Inoperable or Metastatic EGFR Wild-type Non-Small Cell Lung Cancer Patients
Latest Information Update: 13 Jun 2025
At a glance
- Drugs BLI 1401 (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors iplocusmBioPharma; Rgene Corporation
Most Recent Events
- 08 Jun 2025 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.
- 08 Jun 2025 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2027.
- 08 Jun 2025 Planned initiation date changed from 1 Jan 2025 to 1 Jan 2026.